Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efinopegdutide

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM12525A

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: $870.0 million Upfront Cash: $10.0 million

            Deal Type: Licensing Agreement August 04, 2020

            Details:

            Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HM15211

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM15211

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2020

            Details:

            The novel drug is under development with the company’s Lapscovery, a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly administration.